Q-omics provides the consensus-scored BTBD11 profile across patient tissues and cancer cell-line models. BTBD11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, BTBD11 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, BTBD11 RNA expression shows 17,070 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, THCA, and GBM as cancer lineages where BTBD11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD11 survival associations across molecular data types. BTBD11 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD11 RNA expression–survival associations across cancer types. High BTBD11 expression shows unfavorable associations in LUAD, UVM and KIRC, but favorable associations in ACC, PAAD and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for BTBD11 RNA expression.
This table summarizes BTBD11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BTBD11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD11 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in LUSC, BLCA and UCEC. The THCA box plot shows higher BTBD11 RNA expression in normal versus tumor tissue (log2 FC = −2.932, t-test p < 0.001).
This table shows molecular features associated with BTBD11 in patient tissues and cancer cell lines. In patient samples, BTBD11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BTBD11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
